Improving the Cost-efficiency of Preventive Chemotherapy: Impact of New Diagnostics on Stopping Decisions for Control of Schistosomiasis
Clinical Infectious Diseases · 2024
DOI: 10.1093/cid/ciae020 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Infectious Diseases, 2024. Verfasst von Luc E Coffeng und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Public Health, Erasmus Medical Center, University Medical Center Rotterdam, The Netherlands. Hauptthemen laut MEDLINE: Cost-Benefit Analysis, Schistosoma mansoni, Schistosomiasis mansoni, Parasite Egg Count. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council, Bill & Melinda Gates Foundation, NTD Modelling Consortium.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Control of schistosomiasis (SCH) relies on the regular distribution of preventive chemotherapy (PC) over many years. For the sake of sustainable SCH control, a decision must be made at some stage to scale down or stop PC. These “stopping decisions” are based on population surveys that assess whether infection levels are sufficiently low. However, the limited sensitivity of the currently used diagnostic (Kato-Katz [KK]) to detect low-intensity infections is a concern. Therefore, the use of new, more sensitive, molecular diagnostics has been proposed.
Methods
Through statistical analysis of Schistosoma mansoni egg counts collected from Burundi and a simulation study using an established transmission model for schistosomiasis, we investigated the extent to which more sensitive diagnostics can improve decision making regarding stopping or continuing PC for the control of S. mansoni.
Results
We found that KK-based strategies perform reasonably well for determining when to stop PC at a local scale. Use of more sensitive diagnostics leads to a marginally improved health impact (person-years lived with heavy infection) and comes at a cost of continuing PC for longer (up to around 3 years), unless the decision threshold for stopping PC is adapted upward. However, if this threshold is set too high, PC may be stopped prematurely, resulting in a rebound of infection levels and disease burden (+45% person-years of heavy infection).
Conclusions
We conclude that the potential value of more sensitive diagnostics lies more in the reduction of survey-related costs than in the direct health impact of improved parasite control.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Public Health, Erasmus Medical Center, University Medical Center Rotterdam, The Netherlands.
- Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, University of Oxford.
- Department of Statistics, University of Warwick.
- London Centre for Neglected Tropical Disease Research, School of Public Health, Imperial College London.
- Medical Research Council Centre for Global Infectious Disease Analysis, Department of Infectious Disease Epidemiology, School of Public Health, Imperial College London.
- Centre for Health Informatics, Computing, and Statistics, Lancaster University Medical School, United Kingdom.
ORCID-Profile: Luc E Coffeng
Förderung
- Medical Research Council
- Bill & Melinda Gates Foundation
- NTD Modelling Consortium
- MRC Centre for Global Infectious Disease Analysis
- UK Medical Research Council
- UK Foreign, Commonwealth and Development Office
- FCDO
Zitieren
APA
Coffeng, L. E., Graham, M., Browning, R., Kura, K., Diggle, P. J., Denwood, M., Medley, G. F., Anderson, R. M., & de Vlas, S. J. (2024). Improving the Cost-efficiency of Preventive Chemotherapy: Impact of New Diagnostics on Stopping Decisions for Control of Schistosomiasis. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciae020
Vancouver
Coffeng LE, Graham M, Browning R, Kura K, Diggle PJ, Denwood M, et al. Improving the Cost-efficiency of Preventive Chemotherapy: Impact of New Diagnostics on Stopping Decisions for Control of Schistosomiasis. Clinical Infectious Diseases. 2024. doi:10.1093/cid/ciae020
BibTeX
@article{Coffeng2024,
author = {Coffeng, Luc E and Graham, Matthew and Browning, Raiha and Kura, Klodeta and Diggle, Peter J and Denwood, Matthew and Medley, Graham F and Anderson, Roy M and de Vlas, Sake J},
title = {Improving the Cost-efficiency of Preventive Chemotherapy: Impact of New Diagnostics on Stopping Decisions for Control of Schistosomiasis},
journal = {Clinical Infectious Diseases},
year = {2024},
doi = {10.1093/cid/ciae020}
}
EUVIMED